Alzheimer's gold rush inspires $565M deal between Chinese pharma powerhouse and little German biotech
The ballooning controversy around Biogen and its Alzheimer’s drug isn’t deterring others from the gold rush — and the search is global.
China’s Simcere is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
